MedPageToday
MedPage Today) — ORLANDO — The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here.
More than half of patients with psoriatic arthritis (PsA) had at least…
Read More
TYK2 Inhibitor Scores Two Wins Outside Plaque Psoriasis
Georgianna Schewe
13:29
MedPage Today) — ORLANDO — The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here. More than half of patients with psoriatic arthritis (PsA) had at least…
